I. Campbell

D. Gertig, G. Giles, J. Hopper, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Transforming Growth Factor (cid:1) Receptor 1 Polyalanine Polymorphism and Exon 5 Mutation Analysis in Breast and Ovarian Cancer

D. Eccles, I. Campbell, S. Baxter, 2022 .

Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q.

W. Foulkes, I. Campbell, M. Davis, 1996, Cancer research.

Pre-Invasive Ovarian Mucinous Tumors Are Characterized by CDKN2A and RAS Pathway Aberrations

Kylie L. Gorringe, D. Bowtell, M. Christie, 2012, Clinical Cancer Research.

CDKN 2 A and RAS pathway aberrations . Pre-invasive ovarian mucinous tumors are characterized by Updated

Kylie L. Gorringe, Bowtell, M. Christie, 2012 .

Genetic testing in a cohort of young patients with HER2-amplified breast cancer.

D. Eccles, D. Evans, E. Copson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Enhanced GAB 2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI 3 K Inhibition

Kylie L. Gorringe, M. Pike, J. George, 2015 .

TP53 intron 6 polymorphism and the risk of ovarian and breast cancer.

I. Campbell, R. Gornall, D. Eccles, 1998, British Journal of Cancer.

p53 polymorphism in ovarian and breast cancer

D. Eccles, I. Campbell, B. Dunn, 1996, The Lancet.

Loh and mutation analysis of CDKN2 in primary human ovarian cancers

W. Foulkes, I. Campbell, Matt Davis, 1995, International journal of cancer.

Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites

Jennifer H. Martin, M. Jefford, I. Campbell, 2021, European Journal of Clinical Pharmacology.

The molecular origin and taxonomy of mucinous ovarian carcinoma

Kylie L. Gorringe, S. Fox, N. Traficante, 2019, Nature Communications.

Development and pilot testing of an online decision aid for women considering risk-stratified breast screening

I. Campbell, L. Keogh, L. Forrest, 2022, Journal of community genetics.

Ethical and practical implications of returning genetic research results: two Australian case studies

I. Campbell, A. Trainer, P. Lacaze, 2020, The Medical journal of Australia.

Origin of carcinoma associated fibroblasts

I. Haviv, K. Polyak, I. Campbell, 2009, Cell cycle.

Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer

R. Vierkant, E. Goode, N. Traficante, 2019, Journal of Medical Genetics.

Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei

Kylie L. Gorringe, D. Bowtell, M. Doyle, 2019, BMC Cancer.

The molecular characterisation of unusual subcutaneous spindle cell lesion of breast

S. Fox, M. Debiec‐Rychter, I. Campbell, 2012, Journal of Clinical Pathology.

Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas

G. Rice, M. Quinn, M. Baker, 2003, Molecular carcinogenesis.

Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus

R. Pearson, I. Campbell, W. Phillips, 2006, International journal of cancer.

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

Annette Lee, W. Chung, R. Nussbaum, 2018, Human mutation.

No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer

G. Chenevix-Trench, I. Campbell, D. Choong, 2004, Breast Cancer Research.

Refinement of an ovarian cancer tumour suppressor gene locus on chromosome arm 22q and mutation analysis of CYP2D6, SREBP2 and NAGA

E. Dawson, I. Campbell, E. Bryan, 2000, International journal of cancer.

Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype.

W. Foulkes, G. Capellá, I. Tomlinson, 2019, Cancer cell.

Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors

Kylie L. Gorringe, D. Bowtell, M. Christie, 2015, Genome Medicine.

Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.

I. Campbell, M. Tavassoli, M. Alagoz, 1996, British Journal of Cancer.

Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, A. Whittemore, 2013, Human Genetics.

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

W. Chung, F. Couch, B. Bonanni, 2020, JAMA oncology.

Loss of Heterozygosity Analysis in Ductal Lavage Samples from BRCA1 and BRCA2 Carriers: A Cautionary Tale

I. Campbell, Y. Antill, K. Phillips, 2006, Cancer Epidemiology Biomarkers & Prevention.

Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer

Pejovic, Dicks, Hein, 2015 .

Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study

L. Andrews, I. Campbell, M. Delatycki, 2022, Journal of Medical Genetics.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS Genetics.

The HER 2 I 655 V Polymorphism and Risk of Breast Cancer in Women Age 40 Years 1

D. Gertig, G. Giles, J. Hopper, 2003 .

Short Communication The HER2 I655V Polymorphism and Risk of Breast Cancer in Women Age 40 Years 1

D. Gertig, J. Hopper, M. Southey, 2003 .

Absence of PPP2R1B gene alterations in primary ovarian cancers

I. Campbell, T. Manolitsas, 1999, Oncogene.

Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors

D. Bowtell, M. Christie, M. Doyle, 2015, Genome Medicine.

A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1.

R. Bast, W. Foulkes, G. Stamp, 1994, Human molecular genetics.

GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer.

E. Thomas, I. Campbell, S. Baxter, 2001, Carcinogenesis.

Endometriosis: candidate genes.

E. Thomas, I. Campbell, 2001, Human reproduction update.

No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.

D. Eccles, I. Campbell, D. Choong, 2006, Cancer letters.

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium

Francesmary Modugno, James Paul, Honglin Song, 2015 .

Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.

Dong Liang, Thilo Dörk, Natalia Bogdanova, 2014, Molecular nutrition & food research.

The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women

D. Gertig, G. Giles, J. Hopper, 2005, Breast Cancer Research.

Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.

Kylie L. Gorringe, Manasa Ramakrishna, I. Campbell, 2008, Neoplasia.

Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

I. Campbell, S. Baxter, 2001, Journal of the National Cancer Institute.

Mutation of the ST7 tumor suppressor gene on 7q31.1 is rare in breast, ovarian and colorectal cancers

I. Campbell, D. Choong, David Y. H. Choong, 2001, Nature Genetics.

PIK3CA Mutations in Ovarian Cancer

I. Campbell, W. Phillips, S. Russell, 2005, Clinical Cancer Research.

Utility of stromal lymphocytes in diagnosis and predicting upgrade of B3 breast lesions from core biopsies

Kylie L. Gorringe, E. Provenzano, A. Green, 2022, bioRxiv.

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Wei Lu, Wei Zheng, Mads Thomassen, 2013, Nature Genetics.

Integration of tumour sequencing and case–control data to assess pathogenicity of RAD51C missense variants in familial breast cancer

R. Scott, N. Li, E. Thompson, 2021, npj Breast Cancer.

Human perforin mutations and susceptibility to multiple primary cancers

J. Trapani, C. Gedye, I. Campbell, 2013, Oncoimmunology.

randomization Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study

A. Whittemore, M. Beckmann, A. Hein, 2016 .

Allelo typing of Endometriosis with Adjacent Ovarian Carcinoma Reveals Evidence of a Common Lineage 1

E. Thomas, I. Campbell, Xiuxian Jiang, 2006 .

Mutation of galactose‐1‐phosphate uridyl transferase and its association with ovarian cancer and endometriosis

E. Thomas, I. Campbell, X. Jiang, 1998, International journal of cancer.

Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage.

E. Thomas, I. Campbell, X. Jiang, 1998, Cancer research.

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

W. Chung, D. Steinemann, F. Couch, 2022, Communications Biology.

Genomic organization of the human folate receptor genes on chromosome 11q13.

J. Ragoussis, J. Trowsdale, I. Campbell, 1992, Genomics.

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases

Kylie L. Gorringe, A. Talhouk, R. Vierkant, 2019, Modern Pathology.

Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer.

A. Whittemore, D. Hernandez, L. Kiemeney, 2016, Nature genetics.

Loss of Heterozygosity at the α-Inhibin Locus on Chromosome 2q Is Not a Feature of Human Granulosa Cell Tumors

I. Campbell, W. Roy, A. Hitchcock, 1997 .

Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous

S. Fox, I. Campbell, S. Hunter, 2015, Journal of Clinical Pathology.

An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains.

W. Foulkes, J. Trowsdale, P. Freemont, 1992, Cancer research.

SHORT REPORT Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus

R. Pearson, I. Campbell, W. Phillips, 2006 .

Primary mucinous ovarian neoplasms rarely show germ cell histogenesis

Kylie L. Gorringe, C. Gilks, C. Scott, 2020, Histopathology.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Lara E Sucheston-Campbell, A. Whittemore, M. Beckmann, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour

Samantha E. Boyle, T. Speed, S. Fox, 2015, BMC Cancer.

Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.

R. Scott, E. Thompson, I. Campbell, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advances in Brief The Phosphatidylinositol 3-kinase p 85 Gene Is an Oncogene in Human Ovarian and Colon Tumors 1

I. Campbell, S. Rockman, R. Whitehead, 2001 .

Genetic and Epigenetic Analysis of the Putative Tumor Suppressor km23 in Primary Ovarian, Breast, and Colorectal Cancers

I. Campbell, W. Phillips, D. Choong, 2006, Clinical Cancer Research.

Genetic and Epigenetic Analysis of the Putative Tumor Suppressor km 23 in Primary Ovarian , Breast , and Colorectal Cancers

I. Campbell, W. Phillips, D. Choong, 2006 .

Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer.

W. Foulkes, I. Campbell, M. Davis, 1996, Cancer research.

Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial

J. Tie, M. IJzerman, I. Campbell, 2022, Acta oncologica.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

A. Whittemore, M. Beckmann, P. Fasching, 2017, JAMA oncology.

Shared heritability and functional enrichment across six solid cancers

K. D. Sørensen, Stephanie A. Bien, Ali Amin Al Olama, 2019, Nature Communications.

Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women

C. Nickson, G. Mann, I. Campbell, 2018, Breast Cancer Research.

Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk

Yurii B. Shvetsov, Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, 2015, Genetic epidemiology.

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Kylie L. Gorringe, J. George, D. Bowtell, 2011, Clinical Cancer Research.

Co-evolution of tumor cells and their microenvironment.

Izhak Haviv, Kornelia Polyak, I. Haviv, 2009, Trends in genetics : TIG.

Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci.

E. Thomas, I. Campbell, E. Bryan, 1996, Cancer research.

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Stefania Tommasi, Laura Cortesi, Mads Thomassen, 2019, Cancer research.

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

D. Steinemann, F. Couch, B. Bonanni, 2020, Genetics in Medicine.

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

Michael Jones, Peter Kraft, Arnaud Droit, 2017, Nature Genetics.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

D. Steinemann, F. Couch, B. Bonanni, 2016, PloS one.

Molecular cloning of the B-CAM cell surface glycoprotein of epithelial cancers: a novel member of the immunoglobulin superfamily.

W. Foulkes, J. Trowsdale, I. Campbell, 1994, Cancer research.

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

Peter Kraft, Todd L Edwards, Nazneen Rahman, 2016, Cancer discovery.

Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

Wayne A. Phillips, Ian G. Campbell, R. Pearson, 2004, Cancer Research.

The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

I. Campbell, S. Rockman, R. Whitehead, 2001, Cancer research.

Exploiting sequence similarity to validate the sensitivity of SNP arrays in detecting fine-scaled copy number variations

Christopher Leckie, Adam Kowalczyk, Izhak Haviv, 2010, Bioinform..

Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls

Kylie L. Gorringe, R. Scott, M. Doyle, 2015, Breast Cancer Research.

No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing

S. Cross, P. Fasching, C. Vachon, 2016, Journal of Medical Genetics.

Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.

Kylie L. Gorringe, S. Fox, I. Campbell, 2019, Journal of the National Cancer Institute.

Transcriptome ‐ wide association study of breast cancer risk by estrogen ‐ receptor status

Jack A. Taylor, W. Chung, S. Cross, 2020 .

Rare variants in XRCC2 as breast cancer susceptibility alleles

F. Couch, J. Benítez, K. Offit, 2012, Journal of Medical Genetics.

Integration of tumour sequencing and case–control data to assess pathogenicity of RAD51C missense variants in familial breast cancer

R. Scott, E. Thompson, I. Campbell, 2022, NPJ breast cancer.

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression

Kylie L. Gorringe, A. Talhouk, A. Mes-Masson, 2022, npj Precision Oncology.

Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects

Kylie L. Gorringe, E. Ziv, J. Hopper, 2021, npj Breast Cancer.

Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities

Kylie L. Gorringe, D. Etemadmoghadam, D. Bowtell, 2020, The Journal of pathology.

The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density

Kylie L. Gorringe, C. Nickson, S. Fox, 2020, npj Breast Cancer.

The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density

Kylie L. Gorringe, C. Nickson, S. Fox, 2020, npj Breast Cancer.

Molecular comparison of interval and screen‐detected breast cancers

Kylie L. Gorringe, C. Nickson, S. Fox, 2019, The Journal of pathology.

Molecular analysis of PALB2‐associated breast cancers

Kylie L. Gorringe, I. Campbell, S. McInerny, 2018, The Journal of pathology.

A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene

Trevor J Pugh, J. Ragoussis, C. Greenwood, 2021, Genome medicine.

The genetic analysis of a founder Northern American population of European descent identifies FANCI as a candidate familial ovarian cancer risk gene

J. Ragoussis, C. Greenwood, A. Mes-Masson, 2020, medRxiv.

Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes

I. Campbell, S. McInerny, P. James, 2020, Nature Communications.

BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer

Kylie L. Gorringe, J. Visvader, I. Campbell, 2008, Breast Cancer Research and Treatment.

Inferring copy number and genotype in tumour exome data

S. Halgamuge, I. Campbell, P. Cowin, 2014, BMC Genomics.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition

Kylie L. Gorringe, M. Pike, J. George, 2015, Molecular Cancer Therapeutics.

Genomic aberrations of BRCA1-mutated fallopian tube carcinomas.

I. Campbell, K. Gorringe, S. Hunter, 2014, The American journal of pathology.

MicroRNA Genes and Their Target 3′-Untranslated Regions Are Infrequently Somatically Mutated in Ovarian Cancers

Kylie L. Gorringe, Samantha E. Boyle, R. Tothill, 2012, PloS one.

A simple consensus approach improves somatic mutation prediction accuracy

Georgina L Ryland, Maria A Doyle, Tengyu Ma, 2013, Genome Medicine.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Dong Liang, Patrick Neven, Harvey Risch, 2016, Journal of the National Cancer Institute.

Reevaluation of the BRCA2 truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context

Kylie L. Gorringe, A. Kavanagh, S. Fox, 2015, Scientific Reports.

Genetic analysis of benign ovarian tumors

I. Campbell, S. Baxter, N. Thomas, 2003, International journal of cancer.

Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer

Kylie L. Gorringe, R. Pearson, I. Campbell, 2013, Clinical Cancer Research.

Large‐scale genomic analysis of ovarian carcinomas

Kylie L. Gorringe, I. Campbell, K. Gorringe, 2009, Molecular oncology.

Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas

Yurii B. Shvetsov, Kylie L. Gorringe, A. Talhouk, 2021, The Journal of pathology.

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma

Yurii B. Shvetsov, Kylie L. Gorringe, A. Talhouk, 2021, medRxiv.

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.

Harvey Risch, Yian A Chen, Mads Thomassen, 2018, Cancer research.

University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch,

F. Couch, B. Bonanni, O. Olopade, 2013 .

When Is “Type I” Ovarian Cancer Not “Type I”? Indications of an Out-Dated Dichotomy

Kylie L. Gorringe, I. Campbell, K. Gorringe, 2018, Front. Oncol..

Genome-wide significant risk associations for mucinous ovarian carcinoma

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Genetics.

Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification?

Kylie L. Gorringe, Y. Chiew, A. deFazio, 2011, Clinical Cancer Research.

Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium

L. Kiemeney, R. Vierkant, T. Sellers, 2011, PloS one.

CONTRA: copy number analysis for targeted resequencing

Jason Li, Saman K. Halgamuge, Richard Lupat, 2012, Bioinform..

Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2016, Oncotarget.

Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs

E. Thompson, I. Campbell, S. McInerny, 2018, Breast Cancer Research.

An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Kylie L. Gorringe, J. Christensen, R. Pearson, 2012, The Journal of clinical investigation.

Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families

M. Southey, G. Chenevix-Trench, I. Makunin, 2015, Journal of Medical Genetics.

RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary

Georgina L Ryland, David D L Bowtell, Maria A Doyle, 2013, The Journal of pathology.

Analysis of RAD51D in Ovarian Cancer Patients and Families with a History of Ovarian or Breast Cancer

D. Eccles, E. Thompson, I. Campbell, 2013, PloS one.

Analysis of KLLN as a high-penetrance breast cancer predisposition gene

D. Eccles, E. Thompson, I. Campbell, 2012, Breast Cancer Research and Treatment.

Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast

Kylie L. Gorringe, S. Fox, A. Dobrovic, 2015, Breast Cancer Research.

Common variants at the CHEK 2 gene locus and risk of epithelial ovarian cancer

Pejovic, Dicks, Hein, 2015 .

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Kylie L. Gorringe, S. Fox, P. Fasching, 2020, Modern Pathology.

Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer

Kylie L. Gorringe, S. Fox, S. Loi, 2017, Modern Pathology.

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

W. Chung, D. Steinemann, F. Couch, 2019, British Journal of Cancer.

Loss of heterozygosity: what is it good for?

Kylie L. Gorringe, Samantha E. Boyle, R. Tothill, 2015, BMC Medical Genomics.

Mutation analysis of RASK and the 'FLR exon' of NF1 in sporadic ovarian carcinoma.

W. Foulkes, I. Campbell, P. Englefield, 1994, European journal of cancer.

Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

Leah E. Mechanic, F. Couch, D. Bowtell, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects

Kylie L. Gorringe, E. Ziv, J. Hopper, 2021, NPJ breast cancer.

Mutations in RECQL are not associated with breast cancer risk in an Australian population

E. Thompson, I. Campbell, S. McInerny, 2018, Nature Genetics.

Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene

Trevor J Pugh, J. Ragoussis, C. Greenwood, 2023, Genes.

Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants

R. Scott, I. Campbell, S. McInerny, 2022, Journal of the National Cancer Institute.

Homologous recombination DNA repair defects in PALB2-associated breast cancers

I. Hickie, L. Lipton, A. Shelling, 2019, npj Breast Cancer.

Prospective Validation of the NCI Breast Cancer Risk Assessment Tool and the Autodensity Mammographic Density Tool on 40,000 Australian Screening Program Participants

C. Nickson, Y. Arzhaeva, G. Mann, 2018, Journal of Global Oncology.

Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility

I. Campbell, M. Young, P. James, 2018, Genetics in Medicine.

Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2018, British Journal of Cancer.

Assessing the genetic architecture of epithelial ovarian cancer histological subtypes

A. Whittemore, L. Kiemeney, M. Beckmann, 2016, Human Genetics.

COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration

Peter Kraft, Mads Thomassen, Daniel J. Park, 2013, Breast Cancer Research.

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Communications.

Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver

J. George, D. Etemadmoghadam, S. Fereday, 2014, Clinical Cancer Research.

Biology of Human Tumors Genomic Classi fi cation of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP 53-Mutant Tumors and Identi fi es NRAS as an Oncogenic Driver

J. George, D. Etemadmoghadam, S. Fereday, 2014 .

Identification of Candidate Growth Promoting Genes in Ovarian Cancer through Integrated Copy Number and Expression Analysis

Terence P. Speed, Manasa Ramakrishna, Ian G. Campbell, 2010, PloS one.

Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.

Katherine M. Tucker, W. Chung, R. Nussbaum, 2018, Journal of the National Cancer Institute.

Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.

G. Chenevix-Trench, E. Thomas, I. Campbell, 1998, Cancer research.

LCC15-MB Cells are MDA-MB-435: A Review of Misidentified Breast and prostate cell lines

M. Waltham, I. Campbell, J. Rae, 2004, Clinical & Experimental Metastasis.

Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)

Dong Liang, Brooke L. Fridley, Jennifer A. Doherty, 2015, Journal of genetics and genome research.

Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer.

G. W. Stamp, W. Foulkes, G. Stamp, 1993, British Journal of Cancer.

Prohibitin 3' untranslated region polymorphism and breast cancer risk.

D. Eccles, I. Campbell, James Allen, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Null Results in Brief Prohibitin 3 Untranslated Region Polymorphism and Breast Cancer Risk

D. Eccles, I. Campbell, James Allen, 2003 .

Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

Simon G. Coetzee, A. Whittemore, M. Beckmann, 2022, Journal of the National Cancer Institute.

MIRAGAA - a methodology for finding coordinated effects of microRNA expression changes and genome aberrations in cancer

James Bailey, Peter J. Stuckey, Izhak Haviv, 2010, Bioinform..

Are there any more ovarian tumor suppressor genes? A new perspective using ultra high‐resolution copy number and loss of heterozygosity analysis

Kylie L. Gorringe, Samantha E. Boyle, M. Anglesio, 2009, Genes, chromosomes & cancer.

Genetic Analysis of Cancer-Implicated MicroRNA in Ovarian Cancer

Kylie L. Gorringe, I. Campbell, K. Gorringe, 2008, Clinical Cancer Research.

High‐resolution copy number arrays in cancer and the problem of normal genome copy number variation

I. Campbell, K. Gorringe, 2008, Genes, chromosomes & cancer.

No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas

Kylie L. Gorringe, S. Fox, M. Trivett, 2008, Nature Genetics.

Genome-wide, high-resolution detection of copy number, loss of heterozygosity, and genotypes from formalin-fixed, paraffin-embedded tumor tissue using microarrays.

S. Ogawa, D. Bailey, E. Thompson, 2007, Cancer research.

Mutation analysis of EP300 in colon, breast and ovarian carcinomas

Elisabeth Dawson, E. Dawson, I. Campbell, 2002, International journal of cancer.

Genetic changes in tumour microenvironments

I. Haviv, I. Campbell, W. Qiu, 2011, The Journal of pathology.

Copy number analysis of ductal carcinoma in situ with and without recurrence

Kylie L. Gorringe, S. Fox, A. Dobrovic, 2015, Modern Pathology.

Loss of heterozygosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF2 at 22q12.

W. Foulkes, I. Campbell, P. Englefield, 1994, British Journal of Cancer.

Mutational Landscape of Ovarian Adult Granulosa Cell Tumors from Whole Exome and Targeted TERT Promoter Sequencing

I. Campbell, S. Chu, Kaushalya C. Amarasinghe, 2018, Molecular Cancer Research.

Image-guided sampling reveals increased stroma and lower glandular complexity in mammographically dense breast tissue

I. Haviv, M. Southey, M. Jenkins, 2011, Breast Cancer Research and Treatment.

Evidence that Endometriosis Behaves in a Malignant Manner

E. Thomas, I. Campbell, 2000, Gynecologic and Obstetric Investigation.

Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape

E. Rakha, I. Campbell, K. Gorringe, 2018, Breast Cancer Research.

Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer cells

M. Quinn, M. Baker, I. Campbell, 2006, Molecular carcinogenesis.

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

A. Whittemore, W. Chung, L. Kiemeney, 2022, European Journal of Human Genetics.

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

F. Couch, O. Olopade, J. Benítez, 2021, Journal of the National Cancer Institute.

Breast-Cancer Stromal Cells with TP 53 Mutations

I. Haviv, K. Polyak, I. Campbell, 2008 .

Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma

Samantha E. Boyle, Yuker Wang, E. Thompson, 2012, Breast Cancer Research and Treatment.

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

D. Steinemann, F. Couch, O. Olopade, 2017, Journal of Clinical Oncology.

The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma

S. Fox, A. Green, E. Rakha, 2020, npj Breast Cancer.

The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma

S. Fox, A. Green, E. Rakha, 2020, npj Breast Cancer.

Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma

Kylie L. Gorringe, S. Fox, A. Green, 2019, The Journal of pathology.

Whole genome SNP arrays using DNA derived from formalin‐fixed, paraffin‐embedded ovarian tumor tissue

Shane Herbert, E. Thompson, I. Campbell, 2005, Human mutation.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2021, Nature Communications.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Therapeutic options for mucinous ovarian carcinoma☆

Kylie L. Gorringe, N. Traficante, S. Fereday, 2020, Gynecologic oncology.

Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features

Kylie L. Gorringe, S. Fox, S. Lakhani, 2017, Clinical Cancer Research.

Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer

Jason I. Griffiths, D. Bowtell, A. Bild, 2021, Cancers.

Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk

Dong Liang, Brooke L. Fridley, Jennifer A. Doherty, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk.

W. Willett, L. Kiemeney, M. Pike, 2018, Cancer research.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Dennis J. Hazelett, 2017, Nature Genetics.

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

Brooke L. Fridley, Matthias W. Beckmann, Peter A. Fasching, 2013, Nature Genetics.

Cancer Therapy : Clinical IL 6-STAT 3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Kylie L. Gorringe, J. George, D. Bowtell, 2011 .

Monogenic and polygenic determinants of sarcoma risk: an international genetic study.

David M. Thomas, R. Sarin, J. Blay, 2016, The Lancet. Oncology.

Unselected Women's Experiences of Receiving Genetic Research Results for Hereditary Breast and Ovarian Cancer: A Qualitative Study.

I. Campbell, M. Young, P. James, 2021, Genetic testing and molecular biomarkers.

FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.

Eliseos J. Mucaki, F. Couch, B. Bonanni, 2015, Human molecular genetics.

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

David G. Morris, Kylie L. Gorringe, M. Pike, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia

A. Whittemore, L. Kiemeney, K. Stefánsson, 2015, Nature Genetics.

Common origins of MDA-MB-435 cells from various sources with those shown to have melonoma properties

Susan J. Ramus, Mark Waltham, Ian G. Campbell, 2004, Clinical & Experimental Metastasis.

Genetic and Epigenetic Analysis of CHEK2 in Sporadic Breast, Colon, and Ovarian Cancers

I. Campbell, D. Choong, Ian G Campbell, 2006, Clinical Cancer Research.

Genetic and Epigenetic Analysis of CHEK 2 in Sporadic Breast , Colon , and Ovarian Cancers

I. Campbell, D. Choong, Louise H. Williams, 2006 .

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

Jane E. Carpenter, A. Whittemore, S. Cross, 2016, Breast Cancer Research.

Syddansk Universitet Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12 p 11 locus

Jane E. Carpenter, Jaana M. Hartikainen, S. Cross, 2016 .

Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study.

Yurii B. Shvetsov, Lara E Sucheston-Campbell, A. Whittemore, 2015, Gynecologic oncology.

Familial colorectal cancer

L. Lipton, I. Campbell, M. S. Lung, 2015, Internal medicine journal.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

A. Whittemore, P. Fasching, R. Vierkant, 2018, Mayo Clinic proceedings.

Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors

Kylie L. Gorringe, D. Bowtell, M. Christie, 2015, Genome Medicine.

No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer.

I. Campbell, D. Eccles, P. Englefield, 1997, British Journal of Cancer.

Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study.

A. Whittemore, L. Kiemeney, M. Beckmann, 2016, International journal of epidemiology.

Mendelian randomization Association of vitamin D levels and risk of ovarian cancer : a Mendelian randomization study

A. Whittemore, L. Kiemeney, M. Beckmann, 2016 .

Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue

R. Tothill, S. Fox, I. Campbell, 2016, Genome Medicine.

Gene Methylation in Breast Ductal Fluid from BRCA1 and BRCA2 Mutation Carriers

Gillian Mitchell, J. Kirk, I. Campbell, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Samantha E. Boyle, T. Speed, S. Fox, 2015, BMC Cancer.

Lossofheterozygosity andamplification onchromosome llqinhuman

W. Foulkes, G. Stamp, I. Campbell, 1993 .

Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis

I. Campbell, A. Hitchcock, R. Watson, 1998, Oncogene.

Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility

Yurii B. Shvetsov, Lara E Sucheston-Campbell, A. Whittemore, 2018, PloS one.

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer

Yurii B. Shvetsov, Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, 2016, Oncotarget.

Molecular Genetic Defects in Endometriosis

E. Thomas, I. Campbell, Ian G. Campbell, 2000, Gynecologic and Obstetric Investigation.

Differential hypermethylation of SOCS genes in ovarian and breast carcinomas

Sergio Wittlin, J. Visvader, I. Campbell, 2004, Oncogene.

High and low mammographic density human breast tissues maintain histological differential in murine tissue engineering chambers

I. Haviv, J. Hopper, M. Southey, 2012, Breast Cancer Research and Treatment.

The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing

L. Kiemeney, M. Pike, M. Beckmann, 2011, Clinical Cancer Research.

Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study

Kylie L. Gorringe, R. Scott, E. Thompson, 2021, NPJ breast cancer.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

W. Chung, M. Beckmann, P. Fasching, 2019, npj Breast Cancer.

Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study.

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2016, International journal of epidemiology.

Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours

Kylie L. Gorringe, D. Bowtell, M. Doyle, 2020, BMC Research Notes.

Genistein-induced proteome changes in the human endometrial carcinoma cell line, ishikawa

G. Rice, M. Quinn, M. Larsen, 2006, Clinical Proteomics.

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

A. Whittemore, L. Kiemeney, M. Pike, 2015, Nature Communications.

Microsomal epoxide hydrolase polymorphism and susceptibility to ovarian cancer.

I. Campbell, S. Baxter, D. Choong, 2002, Cancer letters.

Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape

Kylie L. Gorringe, E. Rakha, I. Campbell, 2018, Breast Cancer Research.

Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer

D. Eccles, I. Campbell, S. Baxter, 2002, Breast Cancer Research.

Oncolysis of human ovarian cancers by echovirus type 1

I. Campbell, D. Shafren, R. D. Barry, 2005, International journal of cancer.

Discussion: Ovarian Cancer Prevention

A. Berchuck, I. Campbell, M. Brewer, 2003 .

FGFR2 mutations are rare across histologic subtypes of ovarian cancer.

P. Pollock, S. Byron, P. Goodfellow, 2010, Gynecologic oncology.

Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases

Trevor J Pugh, J. Ragoussis, C. Greenwood, 2023, Frontiers in Oncology.

Human genome meeting 2016

Kumar Kshitij Patel, A. Pang, W. Chung, 2016, Human Genomics.

Compromized DNA repair as a basis for identification of cancer radiotherapy patients with extreme radiosensitivity.

E. Thompson, I. Campbell, P. Lobachevsky, 2016, Cancer letters.

Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer.

D. Eccles, I. Campbell, S. Baxter, 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Polymorphic variation in CYP19 and the risk of breast cancer.

D. Eccles, I. Campbell, S. Baxter, 2001, Carcinogenesis.

rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2018, International journal of molecular sciences.

Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome

A. Whittemore, M. Pike, M. Beckmann, 2013, Cancer Epidemiology, Biomarkers & Prevention.

Estimating the proportion of pathogenic variants from breast cancer case–control data: Application to calibration of ACMG/AMP variant classification criteria

A. Spurdle, I. Campbell, P. James, 2022, Human mutation.

Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing

R. Scott, I. Campbell, S. McInerny, 2022, Journal of Medical Genetics.

Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes

Kylie L. Gorringe, I. Campbell, S. McInerny, 2020, Nature Communications.

Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women

Jack A. Taylor, A. Whittemore, L. Kiemeney, 2019, Cancer medicine.

Two newly established cell lines derived from the same colonic adenocarcinoma exhibit differences in EGF‐receptor ligand and adhesion molecule expression

D. Davies, I. Campbell, J. Collins, 1995, International journal of cancer.

Cloning and molecular characterization of monoclonal antibody-defined ovarian tumour antigens

W. Foulkes, J. Trowsdale, I. Campbell, 1995 .

Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.

I. Campbell, D. Bolton, G. Risbridger, 2016, Urologic oncology.

“A Natural Progression”: Australian Women's Attitudes About an Individualized Breast Screening Model

I. Campbell, L. Keogh, L. Forrest, 2019, Cancer Prevention Research.

EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer

David W. Anderson, O. Olopade, G. Mann, 2003, Oncogene.

Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue

Kylie L. Gorringe, R. Tothill, S. Fox, 2016, Genome Medicine.

β‐Catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours

G. Chenevix-Trench, M. Cummings, I. Campbell, 1999, International journal of cancer.

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Yurii B. Shvetsov, A. Whittemore, A. Talhouk, 2023, The journal of pathology. Clinical research.

Reevaluation of RINT1 as a breast cancer predisposition gene

Kylie L. Gorringe, R. Scott, E. Thompson, 2016, Breast Cancer Research and Treatment.

Endometrial progesterone receptor expression during the human menstrual cycle.

E. Thomas, I. Campbell, F. Anthony, 1996, Journal of reproduction and fertility.

Mutations in RECQL are not associated with breast cancer risk in an Australian population

Kylie L. Gorringe, R. Scott, E. Thompson, 2018, Nature Genetics.

Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paper

L. Andrews, Y. Ko, I. Campbell, 2021, BMJ Open.

Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors

Georgia Chenevix-Trench, Ian G. Campbell, Ella R. Thompson, 2008, Breast Cancer Research and Treatment.

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

Jane E. Carpenter, Jack A. Taylor, S. Cross, 2022, Breast Cancer Research.

Mutation and expression analysis of LZTS1 in ovarian cancer.

G. Chenevix-Trench, I. Campbell, J. Arnold, 2006, Cancer letters.

Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer

Hannah Yang, James Paul, Honglin Song, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Variation in NFk B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer

Brooke, Tanja, David N. Rider, 2014 .

Genome-wide association study identifies novel breast cancer susceptibility loci

Lester L. Peters, A. Uitterlinden, D. Cox, 2007, Nature.

ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

James M. Hodge, E. Burnside, Y. Kamatani, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care

P. Butow, I. Campbell, G. Lindeman, 2023, The Medical journal of Australia.

Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci

A. Whittemore, L. Kiemeney, M. Pike, 2017, British Journal of Cancer.

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Communications.

Genome-wide significant risk associations for mucinous ovarian carcinoma

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Genetics.

PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS

Jane E. Carpenter, Lara E Sucheston-Campbell, Ali Amin Al Olama, 2016 .

Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs

Kylie L. Gorringe, E. Thompson, I. Campbell, 2018, Breast Cancer Research.

Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma

Kylie L. Gorringe, Samantha E. Boyle, G. Mann, 2012, Breast Cancer Research and Treatment.

Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma

Ian G. Campbell, Ella R. Thompson, Kylie L. Gorringe, 2012, Hereditary Cancer in Clinical Practice.

Human genome meeting 2016

Kumar Kshitij Patel, Jose Maria Gonzalez-Izarzugaza, A. Pang, 2016, Human Genomics.

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium

A. Whittemore, L. Kiemeney, M. Pike, 2015, Clinical Cancer Research.

A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer

Ella Thompson, Diana M Eccles, Alexander Dobrovic, 2005, BMC Cancer.

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

Jane E. Carpenter, A. Whittemore, S. Cross, 2016, Breast Cancer Research.

Breast cancer risk and the BRCA1 interacting protein CTIP

Kylie L. Gorringe, J. Visvader, I. Campbell, 2008, Breast Cancer Research and Treatment.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Jane E. Carpenter, W. Chung, M. Beckmann, 2019, npj Breast Cancer.

Advances in Brief Localization of an Ovarian Cancer Tumor Suppressor Gene to a 0 . 5cM Region between D 22 S 284 and CYP 2 D , on Chromosome 22 q '

Davis, I. Campbell, Michael, 2006 .

Homologous recombination DNA repair defects in PALB2-associated breast cancers

I. Hickie, L. Lipton, A. Shelling, 2019, npj Breast Cancer.

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS

Jane E. Carpenter, Lara E Sucheston-Campbell, A. Whittemore, 2016, Journal of Medical Genetics.

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

A. Whittemore, S. Cross, R. Nussbaum, 2016, Breast Cancer Research.

Genetic and epigenetic analysis of the TIMP-3 gene in ovarian cancer.

I. Campbell, Louise H. Williams, M. C. Liu, 2007, Cancer letters.

Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer

David N. Rider, A. Whittemore, M. Pike, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk.

L. Kiemeney, M. Pike, P. Fasching, 2018, Cancer research.

Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)

Yurii B. Shvetsov, Lara E Sucheston-Campbell, A. Whittemore, 2015, Journal of genetics and genome research.

Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution.

I. Haviv, K. Polyak, I. Campbell, 2009, Cancer research.

Genetic changes in tumour microenvironments

I. Haviv, I. Campbell, W. Qiu, 2011, The Journal of pathology.

Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer

Kylie L. Gorringe, S. Loi, S. Lakhani, 2017, Modern Pathology.

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium

A. Whittemore, L. Kiemeney, M. Pike, 2015, Clinical Cancer Research.

Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk

Yurii B. Shvetsov, Lara E Sucheston-Campbell, A. Whittemore, 2015, Cancer Epidemiology, Biomarkers & Prevention.

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.

L. Kiemeney, P. Fasching, R. Nussbaum, 2018, Cancer research.

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases

Kylie L. Gorringe, A. Talhouk, R. Vierkant, 2019, Modern Pathology.

Impact of a risk based breast screening decision aid on understanding, acceptance and decision making

I. Campbell, L. Keogh, L. Forrest, 2023, NPJ breast cancer.

FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.

Eliseos J. Mucaki, F. Couch, B. Bonanni, 2015, Human molecular genetics.

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

A. Whittemore, L. Kiemeney, M. Pike, 2016, Cancer discovery.

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Kylie L. Gorringe, J. George, D. Bowtell, 2011, Clinical Cancer Research.

Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.

E. Thompson, I. Campbell, S. McInerny, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing

S. Cross, P. Fasching, C. Vachon, 2016, Journal of Medical Genetics.

Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility

I. Campbell, M. Young, P. James, 2018, Genetics in Medicine.

Exploiting sequence similarity to validate the sensitivity of SNP arrays in detecting fine-scaled copy number variations

Kylie L. Gorringe, I. Haviv, C. Leckie, 2010, Bioinform..

Compromized DNA repair as a basis for identification of cancer radiotherapy patients with extreme radiosensitivity.

E. Thompson, I. Campbell, P. Lobachevsky, 2016, Cancer letters.

Functional polymorphisms in the TERT promoter are associated with risk of serious ovarian and breast cancer

J. Chang-Claude, E. Goode, H. Pickett, 2012, Hereditary Cancer in Clinical Practice.

A simple consensus approach improves somatic mutation prediction accuracy

Tengyu Ma, M. Doyle, I. Campbell, 2013, Genome Medicine.